Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Visium Asset Management and Sage Therapeutics, Inc. (SAGE)

SAGE Therapeutics Inc (NASDAQ:SAGE) has recently been included in a filing by Jacob Gottlieb‘s Visium Asset Management. According to the 13G filing with the US Securities and Exchange Commission, Visium currently owns 5.9% of SAGE Therapeutics, which represent around 5.9% of the company’s outstanding stock. This compares with the 902,948 shares that Visium disclosed in its last 13F filing, for the third quarter of 2015.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Visium Asset Management, 1,893,009 1,893,009 1,893,009 5.9%
JG Asset, 1,893,009 1,893,009 1,893,009 5.9%
Jacob Gottlieb 1,893,009 1,893,009 1,893,009 5.9%
Jacob Gottlieb
Jacob Gottlieb
Visium Asset Management

Page 1 of 11 SEC Filing


Washington, D.C. 20549




Under the Securities Exchange Act of 1934



Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)


(CUSIP Number)

February 1, 2016

(Date of Event Which Requires Filing of this Statement)



Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)**

x Rule 13d-1(c)**

¨ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
** This Schedule is being filed pursuant to Rule 13d-1(b) with respect to Visium Asset Management, LP, JG Asset, LLC and Jacob Gottlieb, and pursuant to Rule 13d-1(c) with respect to certain advisory clients of Visium
Asset Management, LP.

The information required on the remainder of this cover page shall not be deemed to be filed for the
purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Trade (NASDAQ:SAGE) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.